Emerald Investment Advisers LLC Purchases New Shares in Tarsus Pharmaceuticals, Inc. $TARS

Emerald Investment Advisers LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 59,747 shares of the company's stock, valued at approximately $3,760,000. Emerald Investment Advisers LLC owned 0.14% of Tarsus Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Parallel Advisors LLC raised its holdings in shares of Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock valued at $35,000 after buying an additional 291 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock worth $50,000 after buying an additional 558 shares during the period. Comerica Bank grew its holdings in shares of Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company's stock worth $70,000 after buying an additional 705 shares during the last quarter. Truvestments Capital LLC grew its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company's stock worth $74,000 after buying an additional 468 shares during the last quarter. Finally, State of Wyoming acquired a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at about $103,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on TARS. Guggenheim reduced their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research note on Tuesday, July 21st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Oppenheimer boosted their target price on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Finally, Mizuho decreased their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $90.50.

Insider Activity at Tarsus Pharmaceuticals

In other news, Director William J. Phd Link sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the sale, the director directly owned 106,786 shares in the company, valued at approximately $6,633,546.32. This trade represents a 10.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.08, for a total value of $183,384.32. Following the sale, the director directly owned 2,233 shares in the company, valued at $138,624.64. This trade represents a 56.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 39,850 shares of company stock valued at $2,452,821. 9.64% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $72.70 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. Tarsus Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $85.25. The firm has a market capitalization of $3.19 billion, a P/E ratio of -66.70 and a beta of 0.53. The company's fifty day moving average is $63.45 and its two-hundred day moving average is $65.09.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The company had revenue of $173.91 million during the quarter, compared to analysts' expectations of $169.65 million. Analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source